Atugen is an emerging functional genomics company that discovers and validates disease targets in vitro and in vivo, using its technology portfolio of KnockDown™ tools. KnockDown encompasses three tools – antisense molecule technology (GeneBlocs™), ribozymes and synthetic and expressed RNAi molecules, which are useful for the identification and validation of targets for therapeutic intervention.